Purespring Therapeutics has secured $105 million in funding for the development of gene therapies for kidney diseases.
Purespring Therapeutics recently completed a funding round, raising $105 million. The round was led by Sofinnova Partners, with participation from Forbion, Glide Healthcare, and Syncona Limited.
The funds will primarily support the initiation of a Phase 1/2 clinical study for Purespring's lead candidate targeting IgA nephropathy (IgAN). IgAN is a kidney disease characterized by the overproduction of antibodies that accumulate in the kidneys, leading to damage and potential organ failure.
Purespring aims to use adeno-associated viruses (AAVs) as a delivery mechanism for its gene therapies, focusing on the kidneys. The company's approach involves targeting podocytes, specialized cells implicated in renal diseases.
Purespring has showcased preclinical data and published research validating its therapeutic strategy. The company's advancements in gene therapy could play a crucial role in shaping future therapeutic options for kidney diseases.
Purespring's CEO, Julian Hanak, expressed optimism about the company's future and the potential to stop, reverse, and cure kidney diseases. The company will present its IgAN data at the upcoming American Society of Nephrology's Kidney Week meeting.